Daxdilimab Reduces Disease Activity in Discoid Lupus Study
The IgG1 monoclonal antibody daxdilimab was associated with a significant drop in disease activity, with a favorable safety profile in patients with moderate-to-severe discoid lupus erythematosus.
Ähnliche Seiten
AbbVIe's Zumilokibart Meets Phase 2 Goal In Atopic Dermatitis Study | 30.09.26 | finanzen.ch
PAHO and Canada’s Bruyère Health Research Institute strengthen partnership to advance disease elimination in the Americas - PAHO/WHO | Pan American Health Organization